Today: 29 June 2026
Browse Category

NASDAQ:DYN 7 October 2025 - 4 January 2026

Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Dyne Therapeutics shares fell 16.9% to $18.44 after announcing a $300 million stock offering. SLM Corp dropped 15%, Kontoor Brands slid 9.5%, and Waystar Holding lost 8.4%. Major indexes were little changed as investors awaited the Federal Reserve’s interest-rate decision. The U.S. 10-year Treasury yield hovered near 4.19%.
10 December 2025
···········
Top US Stock Market Losers Today (December 9, 2025): HURA, Phreesia, Virgin Galactic, SLM, Gogo and More

Top US Stock Market Losers Today (December 9, 2025): HURA, Phreesia, Virgin Galactic, SLM, Gogo and More

TuHURA Biosciences plunged 36.9% after announcing a $15.6 million direct offering with warrants, triggering heavy dilution concerns. Phreesia, Euda Health, SLM Corp, Virgin Galactic, and Gogo each fell more than 15%. Major indexes stayed mostly flat, with the Dow up 0.2% and the S&P 500 up 0.1% as traders awaited the Federal Reserve’s policy decision.
9 December 2025
··········
Dyne Therapeutics Stock Soars on Duchenne Trial Data: What December 8 Means for DYN Investors

Dyne Therapeutics Stock Soars on Duchenne Trial Data: What December 8 Means for DYN Investors

Dyne Therapeutics shares jumped 14% to $23.20 by mid-afternoon Monday after the company reported its Phase 1/2 DELIVER trial in Duchenne muscular dystrophy met its primary endpoint. The stock touched an intraday high near $25.68 on volume over 2.5 million shares. Dyne plans to seek U.S. accelerated approval in 2026. The company reported $792 million in cash as of Q3 2025.
8 December 2025
·
Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts

Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts

Dyne Therapeutics shares jumped over 10% to around $14 after new trial data showed its lead therapy improved muscle function with no serious side effects. The stock is up about 75% in six months. Dyne’s Duchenne drug just received Orphan Drug status in Japan and positive analyst upgrades, with price targets averaging $34. The company ended June with $683.9 million in cash, extending its runway into 2027.
7 October 2025
·

Stock Market Today

  • IMF Research Questions Bonds as Safe Havens in Stock Market Crashes, Suggests Commodities ETFs
    June 28, 2026, 10:12 PM EDT. Recent IMF research reveals that bonds may no longer serve as reliable diversifiers during stock market downturns due to increased positive correlation with stocks since 2019. Traditional wisdom that bonds rise when stocks fall is challenged. Instead, adding commodities like precious metals could offer better portfolio protection. ETFs such as iShares Silver Trust (SLV), which tracks silver bullion and has returned 21.75% annually over five years, and VanEck Rare Earth and Strategic Metals ETF (REMX) provide exposure to these assets. Silver's sharp 147.9% gain in 2025 reflects inflation concerns and industrial demand but also comes with volatility, having dropped 50% since its January peak. Investors should weigh risks carefully when seeking diversification beyond stocks and bonds.

Latest articles

Trump-era loan caps could open door for private lenders in grad school market

Trump-era loan caps could open door for private lenders in grad school market

29 June 2026
July 1 federal loan caps slash Grad PLUS access, forcing many graduate and professional students to seek private loans; Sallie Mae projects up to 70% origination growth over several years, while SoFi reports record student-loan volume—investors now face a real-time test of how much demand shifts to private lenders as federal limits hit.
IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

29 June 2026
IREN Limited (NASDAQ:IREN) plunged 21.3% to $47.21 over five straight down days despite announcing a record $50M+ annual Warriors jersey deal, as investors focused on the company’s not fully contracted $4.4B target ARR and high short interest at 19.74% of float, with Friday’s close near the lowest analyst target.
Go toTop